Hepatitis C - Schering-Plough Drug Gets Fast Track

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

AVI BioPharma's NEUGENE Shows Success Against Deadly Ebola Virus
Genetic Engineering News - AVI BioPharma, Inc. (Nasdaq:AVII), today announced publication of significant research carried out in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The report, published today in Public Library of

Enzo Biochem Shareholders Elect Three Directors at Annual Meeting
Genetic Engineering News - Enzo Biochem, Inc. (NYSE:ENZ) announced the election of three directors at the Company's annual meeting today, as well as approval of the Company's 2005 Equity Compensation Incentive Plan. The three Class III directors, each elected to three year

Enzo Biochem, Inc. Announces Webcast of Annual Meeting
Genetic Engineering News - Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's